A detailed history of New Edge Advisors, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 260 shares of BMRN stock, worth $17,323. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260
Previous 10,885 97.61%
Holding current value
$17,323
Previous $896,000 97.99%
% of portfolio
0.0%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$69.02 - $93.84 $733,337 - $997,050
-10,625 Reduced 97.61%
260 $18,000
Q2 2024

Aug 15, 2024

BUY
$74.43 - $92.22 $790,074 - $978,915
10,615 Added 3931.48%
10,885 $896,000
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $3,017 - $3,564
-36 Reduced 11.76%
270 $23,000
Q4 2023

Feb 13, 2024

BUY
$76.22 - $98.51 $10,213 - $13,200
134 Added 77.91%
306 $29,000
Q3 2023

Nov 14, 2023

SELL
$85.07 - $94.48 $1,190 - $1,322
-14 Reduced 7.53%
172 $15,000
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $39,179 - $45,335
-452 Reduced 70.85%
186 $16,000
Q1 2023

May 12, 2023

SELL
$87.74 - $117.27 $28,603 - $38,230
-326 Reduced 33.82%
638 $62,000
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $78,016 - $104,719
964 New
964 $99,000
Q4 2021

Feb 17, 2022

SELL
$71.72 - $91.47 $454,202 - $579,279
-6,333 Closed
0 $0
Q3 2021

Oct 29, 2021

SELL
$74.77 - $85.47 $1,719 - $1,965
-23 Reduced 0.36%
6,333 $489,000
Q2 2021

Jul 22, 2021

BUY
$75.51 - $84.79 $10,495 - $11,785
139 Added 2.24%
6,356 $530,000
Q1 2021

Apr 26, 2021

BUY
$74.73 - $90.69 $7,473 - $9,069
100 Added 1.63%
6,217 $469,000
Q4 2020

Jan 27, 2021

BUY
$72.61 - $90.2 $186,317 - $231,453
2,566 Added 72.26%
6,117 $536,000
Q3 2020

Nov 03, 2020

BUY
$71.87 - $131.03 $79,631 - $145,181
1,108 Added 45.35%
3,551 $270,000
Q2 2020

Jul 29, 2020

BUY
$79.55 - $124.22 $194,340 - $303,469
2,443 New
2,443 $301,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.